Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM53J6B)

• Drug Name: PDR001 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Melanoma	2C30	Phase 3	[1]
Esophageal squamous cell carcinoma	2E60.1	Phase 2	[2]
Neuroendocrine cancer	2B72.1	Phase 2	[3]
Lymphoma	2A80-2A86	Phase 1	[3]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]

• Cross-matching ID: TTD Drug ID: DM53J6B

Molecule-Related Drug Atlas

Drug(s) Targeting Programmed cell death protein 1 (PD-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nivolumab	DMAB9QE	Melanoma	2C30	Approved	[5]
Tislelizumab	DMGVUO5	Hodgkin lymphoma	2B30	Approved	[6]
MK-3475	DMBYNW0	Melanoma	2C30	Approved	[5]
Pembrolizumab	DMFQEA6	Melanoma	2C30	Approved	[7]
Cemiplimab	DMKMJHE	Cutaneous squamous cell carcinoma	2C30	Approved	[8]
Retifanlimab	DMRKTCP	Neuroendocrine cancer	2B72.1	Approved	[3]
Sintilimab	DMGWR0C	Hodgkin lymphoma	2B30	Approved	[9]
Dostarlimab	DM78NWP	Endometrial cancer	2C76	Approved	[10]
Toripalimab	DMSGA6Z	Demodex blepharitis	1G07	Approved in China	[11]
BGB-A317	DM7NJYC	Hepatocellular carcinoma	2C12.02	Phase 3	[3]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Programmed cell death protein 1 (PD-1)	TTNBFWK	PDCD1_HUMAN	Antagonist	[4]

References

• [1] ClinicalTrials.gov (NCT02967692) A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma (COMBI-i). U.S. National Institutes of Health.
• [2] ClinicalTrials.gov (NCT03785496) Study to Evaluate Efficacy of PDR001 in Patients With Squamous Cell Carcinoma of the Esophagus. U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [6] Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). Expert Opin Investig Drugs. 2020 Dec;29(12):1355-1364.
• [7] Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
• [8] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [9] Sintilimab: First Global Approval. Drugs. 2019 Feb;79(3):341-346.
• [10] Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Future Oncol. 2021 Mar;17(8):877-892.
• [11] Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol. 2022 Jan 12;12:730666.